Halozyme (HALO) Q2 EPS Jumps 69%

Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is outperformance: EPS came in at $1.54 (non-GAAP), surpassing the $1.24 non-GAAP consensus and EPS grew 69.2% year over year, rising from $0.91 in Q2 2024 to $1.54 (non-GAAP), surpassing the $1.24 consensus. Revenue (GAAP) was $325.7 million, exceeding analyst expectations by 13.9% for GAAP total revenue and up 41% year over year. The company also raised its financial guidance for FY2025, pointing to continued momentum in its royalty-driven model. Overall, the quarter was marked by strong growth in royalty streams, expanded partner adoption of key technologies, and increased management confidence about full-year prospects. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Halozyme Therapeutics focuses on developing drug delivery solutions, most notably its ENHANZE technology. ENHANZE is built around a proprietary enzyme designed to enable quick and comfortable subcutaneous administration of drugs. Rather than launching drugs itself, Halozyme licenses its technology to large pharmaceutical companies, earning royalty and milestone payments whenever partners use ENHANZE to create injectable versions of their intravenous medicines.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool